Uncategorized

Seagen Inc. announced that clinically meaningful progression-free survival, a secondary endpoint, was observed in a Phase 2 study evaluating the antibody-drug conjugate ADCETRIS® in combination with the PD-1 inhibitor nivolumab and standard chemotherapy agents doxorubicin and dacarbazine as first-line treatment for early and advanced stage classical Hodgkin lymphoma.

Bristol Myers Squibb announced the first disclosure of primary analysis results from the high-risk, second-line cohort of TRANSCEND FL, an open-label, global, multicenter, Phase 2, single-arm study evaluating Breyanzi® in patients with relapsed or refractory follicular lymphoma .

MaaT Pharma presented positive results from the Early Access Program in Europe involving 111 patients with steroid-refractory or steroid-dependent gastrointestinal acute graft-versus-host Disease treated with MaaT013, at the 2023 American Society of Hematology Annual Meeting.

Genentech, a member of the Roche Group, announced that new data from its CD20xCD3 T-cell engaging bispecific antibody program, including eight oral presentations, were presented at the 65th American Society of Hematology Annual Meeting & Exposition, December 9-12, 2023.

MorphoSys AG announced comprehensive results from the Phase 3 MANIFEST-2 study investigating pelabresib, an investigational BET inhibitor, in combination with the JAK inhibitor ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis.

InnoCare Pharma, a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced that the latest data from InnoCare’s oncology studies were presented at the 65th American Society of Hematology Annual Meeting.

Positive results from the 24-week and long-term extension period of the pivotal ALPHA Phase III trial showed danicopan as add-on to standard of care C5 inhibitor therapy ULTOMIRIS® or SOLIRIS® continued to demonstrate clinical benefit for patients with paroxysmal nocturnal hemoglobinuria who experience clinically significant extravascular hemolysis.

¿Cuán pesado puede ser un elemento químico? Unos científicos han descubierto que algunas estrellas fueron capaces de producir elementos químicos con números másicos mucho mayores de 260, o sea más pesados que cualquier elemento de la tabla peri …

AbbVie and Genmab A/S announced that adult patients with relapsed/refractory follicular lymphoma previously treated with two or more prior therapies experienced strong and durable responses with high overall response and complete response rates when treated with epcoritamab, an investigational, subcutaneously administered T-cell engaging bispecific antibody.

Blueprint Medicines Corporation announced data showcasing its commitment to advance the scientific understanding and treatment of systemic mastocytosis at the 65th American Society of Hematology Annual Meeting and Exposition being held December 9-12 in San Diego.